User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  12.60 0.94% 1,356.80 1,664,037 15:08:30
Bid Price Offer Price High Price Low Price Open Price
1,356.80 1,357.00 1,358.80 1,345.00 1,347.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.00 6,221.00 93.90 14.4 68,262
Last Trade Time Trade Type Trade Size Trade Price Currency
15:08:40 O 147 1,356.9715 GBX

Glaxosmithkline (GSK) Latest News (2)

More Glaxosmithkline News
Glaxosmithkline Investors    Glaxosmithkline Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 JPMORGAN CLAVERHOUSE INVESTMENT TRUST PLC 2.70% 2021-03-31
 BMO UK HIGH INCOME TRUST PLC 5.24% 2021-03-31

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline Forums and Chat

Date Time Title Posts
07/5/202115:01Glaxosmithkline - The recovery26,482
22/2/202112:31GlazoSmithKline - News & Information43
23/1/202114:27In Rude Health!1
20/1/202109:09GLAXOSMITHKLINE WITH CHARTS & NEWS20
06/10/202016:28covid vaccines not needed.. Trump. Calls experimental drugs "miracles from god"2

Add a New Thread

Glaxosmithkline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:08:411,356.971471,994.75O
14:08:301,356.8059800.51AT
14:08:211,357.002533,433.21AT
14:08:081,357.002533,433.21AT
14:08:081,357.004025,455.14AT
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

DateSubject
07/5/2021
09:20
Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,344.20p.
Glaxosmithkline Plc has a 4 week average price of 1,269.20p and a 12 week average price of 1,190.80p.
The 1 year high share price is 1,742.40p while the 1 year low share price is currently 1,190.80p.
There are currently 5,031,076,193 shares in issue and the average daily traded volume is 10,581,767 shares. The market capitalisation of Glaxosmithkline Plc is £68,291,828,243.78.
30/4/2021
13:19
alex1621: I didn't say that GSK and AZN were equivalent? My point was that before the Pfizer bid it was under the cosh, like GSK. AZN was going through a similar malaise to GSK currently. Then it lit up with the Pfizer bid, and the pressure was on Soriot to persuade shareholders to back his pipeline plans. The question I was pondering was whether EW would get similar backing? On 23 June we will learn what the management view is of the pipeline ... if it's not impressive then I think all or part of GSK will be in play.
30/4/2021
09:54
alex1621: It wasn't not so long ago the AZN share price was languishing and Soriot then had to fight off a takeover from Pfizer. He argued that the drug pipeline would soon pay off and shareholders backed him. The situation at GSK seems vaguely similar. I wonder how EW would fare in a similar situation?
29/4/2021
08:09
spyder: I suspect that Goldmans might have been retained by GSK to provide support to the management in defence of a bid or calls for a break-up. The best early approach to this is to get an improvement in the share price.
28/4/2021
13:52
philanderer: Sebastian Skeet, senior analyst at Third Bridge, said: "GSK endured a pretty lacklustre 2020 following a number of pipeline setbacks and Covid-19 disruption. Worryingly, their 2021 performance looks all too familiar. “Not only have existing challenges such as a muted shingrix recovery, late-stage pipeline setbacks, and increased competition around key on-market assets persisted at GSK, but we have seen additional pressures in the form of currency and shareholder activism. "The market will be watching closely when GSK announces its new company strategy and dividend structure in June.” HTTPS://www.standard.co.uk/business/pharmaceuticals/glaxosmithkline-gsk-covid-pandemic-results-q1-b932173.html
28/4/2021
12:16
gateside: So clearly there will be a cut in dividends, but hopefully there will be capital growth from a rising share price.... "At our investor update on 23 June we plan to set out in detail the strategy, growth prospects and financial outlooks for New GSK, including an in-depth review of key marketed and pipeline growth drivers. Alongside these we will provide details of a new distribution policy which reflects the future investment priorities focused on delivering sustainable long-term shareholder value. We anticipate that this new policy will deliver competitive and attractive returns informed by appropriate earnings pay-out ratios through the investment cycle well covered by Free Cash Flow and, importantly, expected growth potential. We expect that aggregate distributions for GSK will be lower than at present. This new policy will be implemented for dividends paid in respect of 2022."
26/4/2021
07:56
xxxxxy: Some comments from the Daily Mail...Fackham Hall, Garstang, United Kingdom, 9 hours agoWas she the best candidate for the job or just filling the female CEO quota? Next time make sure the best available person gets the role even if it is a male!New326?Steve, Nottingham, 33 minutes agoI worked for Saint Gobain and the regional CEOs had targets on how many women in senior roles. I remember the French HR Director in Paris HQ telling me, "If I had 2 candidates for a job and the man was slightly better than the woman the woman would still get the job" and the Saint Gobain share price says it all.New02?DLM, Herts, United Kingdom, 10 hours agoGet rid of her. The share price has tanked she's been at the helm.
20/4/2021
22:02
xxxxxy: GlaxoSmithKline biopharma spinoff to deliver solid sales growth contrary to market scepticism, says City broker2021-04-19 12:15:00Liberum expects a spike in revenue after short-term headwinds this and next year??    GlaxoSmithKline PLC's (LON:GSK) spinoff is expected to deliver above-sector sales growth contrary to market scepticism, analysts at Liberum said.The FTSE 100 group plans to split into two companies in 2022, consumer health and biopharma, and the outlook for the latter is regarded as the benchmark for the success of the spinoff.READ: GlaxoSmithKline shares rally on report activist Elliot has stakeThe City broker looked at the key product and franchise areas that will define GSK's biopharma business over the next decade.Strong organic growth in oncology and vaccines will deliver steady growth from this year until 2030, analysts said, which will allow margin leverage and an earnings profile that is not properly reflected in the valuation.Two recent approvals, bone marrow cancer treatment Blenrep and HIV/AIDS drug cabotegravir, have blockbuster potential depending upon Blenrep's ability to move to earlier lines and cabotegravir's potential in HIV prevention.Alongside the other four lead assets – anaemia treatment daprodustat, RSV vaccine, antibody otilimab and antibiotics gepotidacin – they are estimated to generate peak sales of US$7.4bn (£5.3bn).In Liberum's bear case that drops to US$1.8bn (£1.2bn), but in the bull case it exceeds US$12bn (£8.6bn).Comparing the sales profile to EU peers, biopharma is facing a "challenging" immediate outlook due to strong currency headwind in 2021 and the absorption of headwinds in the established pharma business.Beyond 2022 it "dramatically" improves as the pharma giant is expected to face very few headwinds while some competitors will have notable expiries, such as blood thinner Xarelto at Bayer.GSK will have a £3bn hole to fill after the loss of exclusivity of HIV medication dolutegravir in 2028, but Liberum reckons the cabotegravir family of products can "significantly" offset it, as the ViiV business is expected to reach £5bn sales by the end of the decade.Analysts said investors will be concerned but the expiry needs to be seen in context: it is geographically staggered, with the US to see erosion in 2028 and the EU in 2029, while its impact on the bottom line is less than for a typical blockbuster expiry.Biopharma's underlying (EBIT) margin of 28% is at the low end of the peer group, but it is expected to rise to 30% thanks to a greater number of blockbuster drugs and a higher percentage of sales from specialty areas."In summary, the GSK Biopharma business is well-positioned to deliver steady sales growth from 2021-2027 at least, and versus its EU peers, GSK's growth profile is respectable and under-appreciated," the broker commented.Liberum has a 'buy' stance on the stock with a 1,700p target price.Shares were trading at 1,347.4p on Monday morning, 19% below last year's levels..... proactive
19/4/2021
14:32
poikka: From Proactive: "GSK spinoff is expected to deliver above-sector sales growth contrary to market scepticism, analysts at Liberum said. The FTSE 100 group plans to split into two companies in 2022, consumer health and biopharma, and the outlook for the latter is regarded as the benchmark for the success of the spinoff. Strong organic growth in oncology and vaccines will deliver steady growth from this year until 2030, analysts said, which will allow margin leverage and an earnings profile that is not properly reflected in the valuation. Two recent approvals, bone marrow cancer treatment Blenrep and HIV/AIDS drug cabotegravir, have blockbuster potential depending upon Blenrep’s ability to move to earlier lines and cabotegravir’s potential in HIV prevention. Alongside the other four lead assets – anaemia treatment daprodustat, RSV vaccine, antibody otilimab and antibiotics gepotidacin – they are estimated to generate peak sales of US$7.4bn (£5.3bn). In Liberum’s bear case that drops to US$1.8bn (£1.2bn), but in the bull case it exceeds US$12bn (£8.6bn). Comparing the sales profile to EU peers, biopharma is facing a “challenging” immediate outlook due to strong currency headwind in 2021 and the absorption of headwinds in the established pharma business. Beyond 2022 it “dramatically” improves as the pharma giant is expected to face very few headwinds while some competitors will have notable expiries, such as blood thinner Xarelto at Bayer. GSK will have a £3bn hole to fill after the loss of exclusivity of HIV medication dolutegravir in 2028, but Liberum reckons the cabotegravir family of products can “significantly” offset it, as the ViiV business is expected to reach £5bn sales by the end of the decade. Analysts said investors will be concerned but the expiry needs to be seen in context: it is geographically staggered, with the US to see erosion in 2028 and the EU in 2029, while its impact on the bottom line is less than for a typical blockbuster expiry. Biopharma’s underlying (EBIT) margin of 28% is at the low end of the peer group, but it is expected to rise to 30% thanks to a greater number of blockbuster drugs and a higher percentage of sales from specialty areas. “In summary, the GSK Biopharma business is well-positioned to deliver steady sales growth from 2021-2027 at least, and versus its EU peers, GSK’s growth profile is respectable and under-appreciated,” the broker commented.
16/4/2021
09:05
poikka: GSK has plenty of potential, but its share price is being held back by the pharma R&D costs, hence the talk of lower future returns for shareholders. A sale of CH for some £30bn, would work wonders for GSK's sp, but, as said, leave it wide open to a bid, hence EW preferring to do the splits; therefore from EW's point of view, she needs to get some good news out there pretty damn quick, to lift the share price Best she could do, sans drug/vaccine news, would be to say that she's considering flogging CH.
16/4/2021
06:33
xxxxxy: Hedge fund Elliott Management has built up a multi-billion pound stake in drugmaker Glaxosmithkline, sparking speculation the activist could demand a shake-up at the top of the company.Shares in GSK rose 6.1pc after the investment was revealed as traders bet that Elliott could launch a campaign to boost its flagging stock price. The New York-based firm has a long history of taking minority stakes in businesses it regards as possible takeover targets, and piling pressure on management.The size of Elliott's stake in GSK has not been disclosed. The investment was first reported by the Financial Times.The pharmaceuticals firm's shares are lagging behind rivals' and are down by almost a third since January 2020. They have fallen 14pc since Dame Emma Walmsley became chief executive in April 2017.Some shareholders are said to be disillusioned with Dame Emma's leadership and lack of a scientific background in comparison to the likes of AstraZeneca boss Pascal Soriot, a former vet.She is spinning off the company's consumer health division into a separately listed company, a move supported by many investors who argue it will allow GSK to focus on drug development. However, some shareholders reportedly believe Dame Emma should become head of the consumer company rather than staying in charge of the drugmaking operation.?Markets Hub - GlaxoSmithKlineMoreThe changes will leave the company with a cleaner balance sheet and the firepower needed to invest in its ailing drugs pipeline. The consumer division will be merged with Pfizer's to create a global titan headquartered in the UK, in a separation process which should complete in mid-2022.Dame Emma is not the only pharmaceuticals boss without a science degree. The chief executives of Eli Lilly, Johnson & Johnson, Roche and Merck have business backgrounds. Pfizer boss Albert Bourla is a vet by training, while Novartis and Bristol-Myers Squibb are both run by former medics.AstraZeneca shares have soared by 80pc over the past five years, compared with GSK's 10pc decline over the same period.Glaxo's valuation is also low compared with rivals. Its shares trade at 12 times earnings, while other firms are at a multiple of about 27.The company's £68bn value is significantly lower than AstraZeneca's £97bn, France's Sanofi at £106bn and Swiss drugs giant Novartis which is worth £200bn.GSK declined to comment and Elliott was not available for comment.Bosses at GSK also annonuced that Emmanuel Hanon, head of vaccines research, was leaving after 20 years to join supplements company Viome.Amir Reichman, former head of global vaccines engineering core technologies, left at the beginning of the year, while head of US pharmaceuticals, Jack Bailey, departed in last 2020..... Yahoo Finance
Glaxosmithkline share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210507 14:23:52